COMP <GO>
AUPH vs ABBV // RSI-14 & 200D SMA MOMENTUM
Aurinia Pharmaceuticals Inc (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: AUPH 8
— ABBV 4
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ABBV
LAST: $17.21 (-0.86%) • MKT CAP: $2.29B
rsi-technicals
49.5
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
rsi-technicals
65.1
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AUPH VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AUPH | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.50% | 70.20% | +18.30 | AUPH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.50% | 29.00% | -12.50 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.1x | 33.3x | -12.20 | AUPH | /valuation <GO> |
| Free Cash Flow Yield | 5.92% | 3.47% | +2.45 | AUPH | /fcf-yield <GO> |
| Operating Margin | 37.10% | 24.60% | +12.50 | AUPH | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 6.90% | +61.10 | AUPH | /net-margins <GO> |
| Revenue Growth (YoY) | 20.40% | 8.60% | +11.80 | AUPH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.33 | 5.33 | +3.00 | AUPH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 49.5 | 65.1 | -15.62 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.7x | 113.1x | -106.40 | AUPH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.29B | $513.86B | -$511.57B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AUPH REV | ABBV REV | AUPH GROSS % | ABBV GROSS % | AUPH FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $283.1M | $61.16B | 88.5% | 70.2% | $135.7M | $17.82B |
| FY 2024 | $235.1M | $56.33B | 88.0% | 70.0% | $44.4M | $17.83B |
| FY 2023 | $175.5M | $54.32B | — | — | -$33.5M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AUPH // BETA —
ABBV // BETA 1.15